I Peace, Inc., a leading GMP cell contract development and manufacturing organization (CDMO) specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, has announced the successful creation of new iPS cell lines that are homozygous for HLA A, C, and DPA1. Available to cell therapy developers and pharmaceutical companies as off-the-shelf products in both GMP and research-grade, these new lines represent a critical advancement in allogenic cell therapies.

Derived from a healthy 26-year-old Caucasian male with A+ blood type, I Peace’s new iPSC line possesses a homozygous HLA A haplotype matching over 100 million people (35.91%) in the U.S., facilitating improved compatibility for a significant portion of patients. The new cell line supports therapeutic strategies aimed at reducing immune rejection risks, providing accessible cell therapy options as the industry advances towards broader adoption of autologous therapies.

Advancing Cell Therapy with Enhanced HLA Compatibility

HLA matching plays an essential role in the success of stem cell transplants by increasing compatibility between donor and recipient, thus minimizing the risk of immune rejection and graft-versus-host disease (GvHD). I Peace’s HLA homozygous iPSCs create a pathway for developing safer allogenic cell therapies that could benefit millions of patients while the industry works toward widespread availability of personalized, autologous cell therapies.

"Our iPSC technology marks a significant step toward making regenerative medicine more accessible, especially for those who may not yet have access to personalized cell therapies," said Koji Tanabe, Founder and CEO of I Peace, Inc. "Our goal is to bridge current gaps in cell therapy by providing high-quality, GMP-grade iPS cells that accelerate treatment timelines and improve patient outcomes.”